Neuphoria Therapeutics (NEUP) Other Working Capital Changes (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Other Working Capital Changes of -$11966.0 for Q1 2026, up 94.09% year-over-year from -$6165.3 in Q1 2025, and up 85.96% on a QoQ basis from -$85210.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Other Working Capital Changes data on file, last reported at -$11966.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 94.09% year-over-year to -$11966.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49781.0 (up 71.83% YoY) and the FY2025 annual result came in at -$123304.0, up 11.4% from the prior year.
- Other Working Capital Changes advanced to -$11966.0 in Q1 2026 per NEUP's latest filing, from -$85210.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $132719.0 in Q4 2024 and bottomed at -$202306.0 in Q1 2025.
- The 4-year median for Other Working Capital Changes is -$31104.0 (2025), against an average of -$35523.4.
- Peak annual rise in Other Working Capital Changes reached 481.49% in 2024, while the deepest fall reached 263.3% in 2024.
- Tracing NEUP's Other Working Capital Changes over 4 years: stood at $22824.0 in 2023, then surged by 481.49% to $132719.0 in 2024, then tumbled by 164.2% to -$85210.0 in 2025, then surged by 85.96% to -$11966.0 in 2026.
- Per Business Quant, the three latest NEUP Other Working Capital Changes figures stand at -$11966.0 (Q1 2026), -$85210.0 (Q4 2025), and -$31104.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11,966.00 |
| Mar 31, 2026 | -11,966.00 |
| Dec 31, 2025 | -678,446.00 |
| Dec 31, 2025 | -678,446.00 |
| Sep 30, 2025 | -34,793.00 |
| Sep 30, 2025 | -34,793.00 |
| Jun 30, 2025 | 654,861.00 |
| Jun 30, 2025 | 654,861.00 |
| Mar 31, 2025 | -130,495.00 |
| Mar 31, 2025 | -130,495.00 |
| Dec 31, 2024 | -71,859.00 |
| Dec 31, 2024 | -71,859.00 |
| Sep 30, 2024 | 551.00 |
| Sep 30, 2024 | 551.00 |
| Jun 30, 2024 | 152,309.00 |
| Jun 30, 2024 | 152,309.00 |
| Mar 31, 2024 | -117,493.00 |
| Mar 31, 2024 | -117,493.00 |
| Dec 31, 2023 | -11,987.00 |
| Dec 31, 2023 | -11,987.00 |
| Sep 30, 2023 | -34,793.00 |
| Sep 30, 2023 | -34,793.00 |